

July 25, 2016

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment for the 14th Consecutive Year

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) has been selected for inclusion in the FTSE4Good Index Series of socially responsible investment (SRI).^{*1} The company has now been listed for 14 years in succession, starting in 2003.

The FTSE4Good Index Series is a leading series of SRI indices produced by FTSE Russell^{*2} in order to measure firms' sustainability from the standpoints of environmental, social and governance practices. A number of distinctive standards are applied in order to select constituents, which numbered 160 firms in Japan and 823 worldwide as of the end of June 2016.

Our company's inclusion in FTSE4Good is underpinned by especially high evaluations in 3 of the 14 areas assessed: Corporate Governance, Climate Change, and Customer Responsibility. We have also been selected for inclusion in the MSCI (Morgan Stanley Capital International) Global Sustainability Indexes, another globally-recognized SRI index series, for the last 6 years in succession.

Our responsibility to society, encapsulated in our Corporate Mission, is "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," and we define the implementation of this mission as our "CSR management." We remain committed to the practice of CSR management and the sustainable enhancement of corporate value.



2015 Constituent
MSCI Global
Sustainability Indexes

***1 Socially Responsible Investment (SRI)**

Investment strategy whereby potential investors take into account assessments of a company's policies and actions in respect of corporate social responsibility, environmental issues, and governance, in addition to analysis of financial performance.

***2 FTSE Russell**

A company that delivers tools for investment decision-making on a global scale, including the development and management of numerous indices. Wholly owned by the London Stock Exchange.

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)